Author of

• 17728

  +

  P2.04 - Poster Session with Presenters Present (ID 466)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Mesothelioma/Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 17739

    +

    P2.04-011 - Tumours of the Thymus: Northern Ireland 11 Year Experience (ID 5069)

    14:30 - 14:30  |  Author(s): R. Douglas
    • Abstract

    Background:
    Tumours of the thymus are rare and consensus on their management is lacking. We aimed to assess outcomes of patients diagnosed over the last 11 years.
    
    Methods:
    We identified all patients diagnosed with thymic tumours in Northern Ireland between January 2004 and December 2015 as recorded in the Cancer Registry. Electronic Care Records were used for data collection.
    
    Results:
    Fifty-seven patients were identified, including 9 thymic carcinomas, 44 thymomas, 3 neuroendocrine tumours and 1 with small cell features. Mean age at diagnosis was 62 (16-82) and 26% presented with paraneoplastic phenomena. Of the thymoma patients, the majority presented with early stage disease (45.5% stage 1, 31.8% stage 2) and 86% had surgery. Ten patients received adjuvant radiotherapy (XRT), most received 50G in 20 fractions (#). Of those with advanced disease, only 3 received palliative chemotherapy. Various platinum-based regimes were used. Only 1 patient received any subsequent line of therapy. Generally thymic carcinomas presented later, with > 75% with stage 3 or 4 disease. Despite this, almost half (4/9) had surgery. Additionally, 2 received adjuvant XRT (between 40-50Gy) and 1 adjuvant chemoradiotherapy (Cisplatin/Etoposide, 50Gy 25#). 44.4% of these patients received palliative platinum-based chemotherapy, achieving modest partial responses at best. Median overall survival (OS) for thymoma (1) was 9.2 years compared to 6.2 years for thymic (2) carcinoma (p= 0.036)Figure 1
    
    
    
    Conclusion:
    Thymomas had a significantly better prognosis than thymic carcinomas suggesting that these are 2 different disease processes. The variability in treatments received reflects the lack of information and general consensus. Given the rarity of these tumours, greater emphasis must be placed on collaborative efforts, to increase patient numbers and obtain meaningful results that will increase our understanding of this challenging group of patients and improve outcomes.